SUMMARY Treatment with captopril has proved effective in some patients with resistant heart failure. Since cardiac output responses to captopril treatment are generally small, we infused the positive inotropic agent dobutamine in six patients already receiving captopril to determine whether cardiac output could be augmented without concomitantly increasing myocardial oxygen demands. At low infusion rates of dobutamine (2-5 and 5 ,ug/kg per min), a substantial rise in cardiac output was observed yet myocardial oxygen uptake remained well below baseline (pre-captopril/dobutamine) levels. At higher rates of infusion (10 and 20 ,tg/kg per min) the rise in cardiac output was accompanied by a pronounced increase in myocardial oxygen uptake, and the appearance of chest pain or multifocal ventricular extrasystoles in three patients. These data indicate that captopril treatment combined with low infusion rates of dobutamine can augment cardiac output in the short term, without increasing myocardial oxygen demand.
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The prime pathophysiological features of heart failure include reduced myocardial contractility, oedema, and vasoconstriction. Treatment may be directed at these abnormalities singly or in combination. The vasoconstriction aspect has enjoyed particular attention recently with the advent of vasodilator treatment' 2 and the oral converting-enzyme inhibitor, captopril.3 4 Captopril-induced increases in myocardial performance as assessed by measurements of cardiac output, however, are often not great. 3 Under such circumstances the addition of agents which directly increase myocardial contractility should be beneficial provided that the balance of cardiac oxygen demand and supply is not adversely affected. 
Results
The addition of captopril to digoxin and frusemide treatment induced beneficial haemodynamic responses and clear-cut hormonal changes, the details of which are reported elsewhere for five of the six patients.3 As shown in the Table and Figure, captopril lowered arterial pressure (p<0 001), slowed the pulse rate (p<0025), and thus reduced myocardial oxygen uptake (MVO2) conspicuously (p<0-001) as assessed indirectly (heart rate -systolic arterial pressure product8 9). A concurrent modest decline in pulmonary artery diastolic pressure (an index of left ventricular end-diastolic filling pressure) was observed. The rise in resting cardiac output was minor but statistically significant (p<001). Dobutamine infusion on the fifth day of treatment with captopril induced chest pain in one patient (at 10 gg/kg per min) and frequent multifocal ventricular extrasystoles in two others (at 10 and 20 ,ug/kg per min) so that further dose increments were not employed in these subjects.
Dobutamine-haemodynamic dose-response curves were produced for cardiac output, heart rate, and MVO2, a plateau being reached at a dose of 10 ag/kg per min (Fig.) . At the lowest infusion rate of dobutamine (2-5 ,g/kg per min), cardiac output increased in each of five patients the mean increment being 0 77 1/min, yet arterial pressure, pulse rate, and MVO2 did not increase and pulmonary artery diastolic pressure tended to decline. The cardiac outpatient measurement at this infusion rate for the sixth patient was lost. Doubling the dobutamine infusion (5 ,ug/kg per min) further increased cardiac Ikram, Maslowski, Nicholls output (p<0001 compared with levels before dobutamine) but MVO2 also increased significantly (p<0 01) because of a rise in heart rate. Nevertheless, MVO2 was still well below that for the control (pre-captopril) period (p<0001). Higher rates of dobutamine administration (10 and 20 ,ug/kg per min) again increased cardiac output but at the expense of chest pain or arrhythmia in three patients and a further rise in heart rate and MVO2. Mean arterial pressure and pulmonary artery diastolic pressure showed no tendency to increase during dobutamine infusion, and the decline in the latter index reached levels of statistical significance at the 2 5 (p<005) and the 10 ,ug/kg per min infusion rates (p<0O01) compared with values before dobutamine. All indices had returned to near baseline values 15 minutes after stopping dobutamine infusion.
Discussion
In the treatment of heart failure, vasodilators theoretically should decrease myocardial oxygen demand by lowering preload and/or afterload and thereby reducing left ventricular end-diastolic volume and wall tension. Captopril, by altering the circulating levels of vasoactive hormones, induces arterial (and perhaps venous) dilatation and is reportedly effective in patients with otherwise resistant heart failure.3 4 10 11 The use of sympathomimetic amines for their positive inotropic effect is well established.5 6 These are not, however, without theoretical disadvantages. Apart from their obvious arrhythmogenic potential, myocardial oxygen demands would be expected to rise as a r.esult of increased heart rate and peripheral vasoconstriction. In this respect dobutamine appears to be a most attractive agent in that it minimises the increase in myocardial oxygen demand.7 We surmised that dobutamine administration at certain dose levels, added to a baseline of treatment with captopril, should increase cardiac output yet retain myocardial oxygen requirements at or below baseline (pretreatment) levels. The current study confirms that this is indeed possible. Therefore, the use of captopril combined with low doses of dobutamine appears to offer a rational, safe, and effective means of increasing cardiac performance, in the short term. It remains to be seen whether similar beneficial effects are possible with longer-term combination treatment of converting-enzyme inhibitors and orally active positive inotropic drugs, a number of which are currently under investigation. 
